GlassScriptPhysician profile
Gibbs Wilson
NPI 1649658592
$1,396.14
in general payments reported to CMS, 2019-2025
14 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.27 · 2020: $98.16 · 2021: $339 · 2022: $331 · 2023: $201 · 2024: $226 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.41 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $323.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $296.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $239.46 | 2022-2024 | Farxiga |
| Abbott Laboratories | $104.21 | 2022-2023 | Cardiomems |
| Cleerly, INC. | $87.76 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Portola Pharmaceuticals, LLC | $68.17 | 2020 | |
| Janssen Pharmaceuticals, INC | $65.69 | 2021-2022 | |
| Abiomed | $58.35 | 2022 | |
| Boston Scientific Corporation | $42.53 | 2020-2025 | Watchman Flx |
| Amgen INC. | $42.29 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.22 | 2019-2022 | |
| Pfizer INC. | $17.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.17 | 2022 | |
| Cvrx, INC. | $7.43 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gibbs Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.